Marker and system for auxiliary diagnosis of subcortical ischemic vascular dementia
By using placental growth factor as a marker and electrochemiluminescence detection technology, combined with machine learning algorithms, an efficient SIVD diagnosis system was designed, solving the problem of insufficient sensitivity and specificity of diagnosing SIVD in the prior art, achieving high accuracy Sexual and high specificity diagnostic effects reduce the burden on patients.
Patent Information
- Application Number
- CN202411093993.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art lacks sensitive, specific and easy-to-use biomarkers in the diagnosis of subcortical ischemic vascular dementia (SIVD), resulting in frequent misdiagnosis or missed diagnosis, limited existing tools, and difficult to improve the level of diagnosis and treatment.
Placenta growth factor (PLGF) is used as an auxiliary diagnostic marker, combined with electrochemiluminescence detection technology, an efficient diagnostic system is designed, and plasma PLGF concentration standard ≥6.655pg/mL is set for auxiliary diagnosis, and diagnostic accuracy is optimized through machine learning algorithms.
High accuracy and specificity diagnosis were achieved, with a detection specificity of 97.37% and an AUC value of 0.9021, which significantly improved the accuracy and reliability of the diagnosis, reduced the size of the test sample and reduced the burden on patients.
Smart Images

Figure CN119000651A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical diagnosis, and relates to a marker and a system for assisting diagnosis of subcortical ischemic vascular dementia. Background Art
[0002] Vascular dementia (VaD) is a cognitive disorder caused by cerebrovascular disease. Its prevalence in people over 65 years old is increasing year by year. It has become the second most common type of dementia after Alzheimer's disease. Its pathological mechanism is complex and includes multiple clinical subtypes. Subcortical ischemicvascular dementia (SIVD) is the most common subtype of VaD, with strong homogeneity in clinical phenotype and pathological characteristics.
[0003] At present, the diagnosis of SIVD mainly relies on imaging examinations combined with clinical symptoms and neuropsychological assessments for comprehensive diagnosis. Due to the insidious onset and slow progression of SIVD, the clinical symptoms lack specificity, which can easily lead to misdiagnosis or missed diagnosis. Therefore, it is urgent to find sensitive, specific, simple and easy-to-use biomarkers to improve the clinical diagnosis and treatment of SIVD. For example, some studies have explored the application value of serum β-amyloid protein (Aβ) and tau protein in the early diagnosis of subcortical ischemic vascular dementia. The ELISA method was used to detect the levels of serum Aβ38, Aβ40 and Aβ42, total tau (t-tau) protein and phosphorylated tau (p-tau) protein in 38 SIVD patients, 42 patients with mild cognitive impairment (MCI-V) with subcortical vascular injury characteristics, and 36 normal controls. It was found that the Aβ40 level in the SIVD group was significantly higher than that in the MCI-V group and the control group, and that in the MCI-V group was higher than that in the control group. There was no statistically significant difference in the Aβ38 and Aβ42 levels among the three groups. The tau level in the SIVD group was significantly higher than that in the MCI-V group and the control group, and that in the MCI-V group was higher than that in the control group. The p-tau level in the SIVD group was higher than that in the MCI-V group and the control group, indicating that serum Aβ40 and tau protein can be used as biological indicators for the early diagnosis of SIVD, but lack specificity.
[0004] In summary, there are currently limited tools that can be effectively used to diagnose or assist in the diagnosis of SIVD. Therefore, there is an urgent need to develop new markers or diagnostic systems to expand diagnostic methods and promote the development of the field of early diagnosis of SIVD. Summary of the invention
[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides a marker and system for assisting the diagnosis of subcortical ischemic vascular dementia, develops an efficient diagnostic system, in order to expand diagnostic methods and promote the development of the field of early diagnosis of SIVD.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a marker for assisting the diagnosis of subcortical ischemic vascular dementia, wherein the marker comprises placental growth factor.
[0008] In the present invention, an in-depth comparative analysis was conducted between healthy people and patients with subcortical ischemic vascular dementia, and it was found that the level of placental growth factor (PLGF) in the plasma of patients with subcortical ischemic vascular dementia was significantly higher than that of healthy people.
[0009] In a second aspect, the present invention provides the use of the detection substance of the marker for auxiliary diagnosis of subcortical ischemic vascular dementia described in the first aspect in constructing a system for auxiliary diagnosis of subcortical ischemic vascular dementia.
[0010] Preferably, the detection substance includes reagents and / or devices for detecting the markers for auxiliary diagnosis of subcortical ischemic vascular dementia as described in the first aspect.
[0011] Preferably, the reagents and / or devices include electrochemiluminescent detection reagents and / or devices.
[0012] In a third aspect, the present invention provides a system for assisting the diagnosis of subcortical ischemic vascular dementia, wherein the input data of the system is the concentration of a marker for assisting the diagnosis of subcortical ischemic vascular dementia in a sample to be tested, and the criterion for determining a positive subcortical ischemic vascular dementia is that the concentration of the marker for assisting the diagnosis of subcortical ischemic vascular dementia is ≥6.655 pg / mL.
[0013] The present invention uses PLGF as a marker to design and construct an efficient diagnostic system to achieve high-accuracy detection, with a detection specificity of 97.37% and an AUC value of 0.9021.
[0014] Preferably, the sample to be tested includes plasma. The concentration detection method includes electrochemiluminescence detection method.
[0015] In a fourth aspect, the present invention provides a device for assisting in the diagnosis of subcortical ischemic vascular dementia, the device comprising a detection unit and a determination unit;
[0016] The detection unit is used to perform the following steps:
[0017] Detecting the concentration of the marker for auxiliary diagnosis of subcortical ischemic vascular dementia described in the first aspect in the sample to be tested;
[0018] The determination unit is used to perform the following steps:
[0019] Auxiliary diagnosis is performed according to the system for auxiliary diagnosis of subcortical ischemic vascular dementia described in the third aspect.
[0020] Preferably, the sample to be tested includes plasma.
[0021] Preferably, the detection method comprises electrochemiluminescence detection.
[0022] In the present invention, a corresponding detection device is developed based on the electrochemiluminescence detection (MSD) method, and a device capable of performing high-specificity and accurate diagnosis based on the MCD detection results is developed. The sensitivity of the MSD detection platform can reach fg / mL, and extremely low protein levels in peripheral blood can be accurately quantified, and a small amount of sample is required for detection.
[0023] In a fifth aspect, the present invention provides a computer-readable storage medium having a computer program or instruction stored thereon, which, when executed by a processor, implements the functions of the device for assisting in the diagnosis of subcortical ischemic vascular dementia as described in the fourth aspect.
[0024] In a sixth aspect, the present invention provides a computer device comprising a memory and a processor, wherein the memory stores a computer program or instructions, and when the computer program or instructions are executed by the processor, the functions of the device for assisting in diagnosing subcortical ischemic vascular dementia as described in the fourth aspect are realized.
[0025] Compared with the prior art, the present invention has at least the following beneficial effects:
[0026] The present invention finds that placental growth factor is associated with subcortical ischemic vascular dementia based on MCD detection, and the level of placental growth factor in the plasma of patients with subcortical ischemic vascular dementia is significantly higher than that of healthy people. The present invention further designs and constructs an efficient auxiliary diagnosis system to achieve high-accuracy detection, with a detection specificity of 97.37% and an AUC value of 0.9021. Moreover, the detection is performed using the MSD ultra-high sensitivity detection technology, and the accuracy and reliability of the results are greatly improved. At the same time, the sample amount required for the detection is greatly reduced, the blood drawing burden on patients is alleviated, and this is conducive to clinical promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the result graph of the receiver operating curve analysis;
[0028] Figure 2 This is a graph showing the correlation between PLGF expression levels and neuropsychological assessment data. DETAILED DESCRIPTION
[0029] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0030] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0031] In the specific embodiment of the present invention, the plasma PlGF levels of healthy people and patients with subcortical ischemic vascular dementia were deeply compared and analyzed based on the electrochemiluminescence detection (MSD) method, and the diagnostic value of PLGF for healthy people and SIVD was further analyzed, and it was verified that PLGF has good specificity and accuracy for the diagnosis of SIVD. Based on the receiver operating characteristic curve (ROC), when the plasma PLGF concentration was less than 6.655 pg / mL, 97.37% of the subjects were able to exclude the possibility of SIVD; when the detection concentration was greater than or equal to 6.655 pg / mL, 70% of the subjects were considered to be diagnosed with SIVD, and the area under the curve (AUC) value was 0.9021. In addition, the correlation between the plasma PLGF expression level of SIVD patients and the neuropsychological evaluation data was analyzed. The plasma PIGF concentration of SIVD patients was negatively correlated with the overall cognitive function, information processing speed, language function and visual-spatial function. It was shown that PLGF can be applied to the diagnosis of SIVD disease, which is helpful to improve the accuracy of clinical diagnosis and reduce the disease burden of patients.
[0032] In a specific embodiment of the present invention, a product for assisting in the diagnosis of subcortical ischemic vascular dementia is provided, and the product includes a reagent and / or device for detecting PLGF.
[0033] In a specific embodiment of the present invention, a system for assisting in the diagnosis of subcortical ischemic vascular dementia is provided, which is constructed based on training of a machine learning algorithm (such as logistic regression, decision tree, random forest or support vector machine, etc.), wherein the input data of the system is the concentration of PLGF, and the criterion for determining a positive subcortical ischemic vascular dementia is that the concentration of the PLGF is ≥6.655 pg / mL.
[0034] In a specific embodiment of the present invention, a device for auxiliary diagnosis of subcortical ischemic vascular dementia can also be provided, the device comprising a detection unit and a determination unit; the detection unit is used to execute the following steps: detecting the concentration of PLGF in the sample to be tested; the determination unit is used to execute the following steps: performing auxiliary diagnosis according to the system for auxiliary diagnosis of subcortical ischemic vascular dementia.
[0035] In a specific embodiment of the present invention, a computer-readable storage medium is provided, on which a computer program or instruction is stored, and when the computer program or instruction is executed by a processor, the function of the device for assisting in diagnosing subcortical ischemic vascular dementia is realized. Or a computer device is provided, including a memory and a processor, and the memory stores a computer program or instruction, and when the computer program or instruction is executed by the processor, the function of the device for assisting in diagnosing subcortical ischemic vascular dementia is realized.
[0036] Example 1
[0037] This example analyzes the plasma PLGF concentrations of different populations.
[0038] The concentration of plasma PlGF in 40 healthy people and 70 SIVD patients was measured by MSD ultrasensitive detection technology. The specific detection process includes:
[0039] (1) Before the experiment, rewarm the samples and the electrochemiluminescence detection kit in advance; (2) Add the standard and the sample to be tested to the 96-well detection plate and incubate at 25°C for 1 hour; (3) Add cleaning solution to each well and wash it three times, then add the detection antibody and incubate it at 25°C for 1 hour; (4) Add cleaning solution again and wash it three times, finally discard the cleaning solution, pat the 96-well plate dry, and add the plate reader; (5) Read the 96-well plate on the electrochemiluminescence detection imager to obtain the detection data.
[0040] The test results showed that the plasma PLGF concentration in SIVD patients was significantly higher than that in healthy people, indicating that PLGF has the potential to serve as a diagnostic marker for SIVD.
[0041] Example 2
[0042] This example further analyzes the reference value of plasma PLGF levels for disease diagnosis.
[0043] Based on the detection data of Example 1, a system for assisting diagnosis of subcortical ischemic vascular dementia was constructed based on machine learning algorithm training, and the critical value of plasma PLGF concentration was set to 6.655 pg / mL. Receiver operating curve (ROC) analysis was performed using SPSS26.0 software. The results are as follows: Figure 1As shown, the sensitivity of disease diagnosis is 70%, the specificity is 97.37%, and the AUC value is 0.9021, indicating that the auxiliary diagnosis system designed by the present invention has good diagnostic efficacy for the diagnosis of SIVD.
[0044] Example 3
[0045] The correlation between plasma PLGF expression levels and neuropsychological assessment data of SIVD patients was further analyzed using computer analysis software.
[0046] The specific analysis process includes:
[0047] SPSS26.0 software was used to perform partial correlation analysis to evaluate the correlation between plasma PLGF expression levels and cognitive function in SIVD patients. The age and gender of the subjects were used as control factors to exclude their potential influence on the analysis results, so as to obtain more reliable data analysis results. The results were interpreted according to the correlation coefficient (r) and P value calculated by SPSS26.0 software. When the P value was less than 0.05, it was considered that the plasma PLGF expression level was significantly correlated with cognitive function.
[0048] The analysis results are as follows Figure 2 As shown in the results, the plasma PLGF concentration of SIVD patients was negatively correlated with overall cognitive function, information processing speed, language function and visual-spatial function. That is, the higher the plasma PLGF concentration of SIVD patients, the more severe the dementia symptoms and the more obvious the impairment in multiple cognitive areas. This further indicates that PLGF can be used as a diagnostic marker for SIVD.
[0049] In summary, the plasma PLGF expression level measured by the MSD ultra-high sensitivity detection technology of the present invention can well distinguish healthy people from SIVD. At the same time, the plasma PLGF concentration value is closely related to the severity of the disease and can be used as an indicator for monitoring disease progression and evaluating treatment effects. The present invention applies plasma PLGF to the technology of SIVD disease diagnosis for the first time, which helps to improve the accuracy of clinical diagnosis and also reduces the disease burden of patients.
[0050] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. Application of a detection substance for a marker for assisting diagnosis of subcortical ischemic vascular dementia in constructing a system for assisting diagnosis of subcortical ischemic vascular dementia; The markers include placental growth factor; The detection substance includes reagents and / or equipment for detecting the marker; The reagents and / or devices include electrochemiluminescent detection reagents and / or devices.
2. A system for assisting diagnosis of subcortical ischemic vascular dementia, characterized in that: The input data of the system is the concentration of placental growth factor in the sample to be tested, and the standard for judging the positive of subcortical ischemic vascular dementia is that the concentration of placental growth factor is ≥6.655 pg / mL.
3. The system for assisting diagnosis of subcortical ischemic vascular dementia according to claim 2, characterized in that: The sample to be tested includes plasma.
4. The system for assisting diagnosis of subcortical ischemic vascular dementia according to claim 2 or 3, characterized in that: The method for detecting the concentration of placenta growth factor includes electrochemiluminescence detection method.
5. A device for assisting diagnosis of subcortical ischemic vascular dementia, characterized in that: The device comprises a detection unit and a determination unit; The detection unit is used to perform the following steps: Detecting the concentration of placental growth factor in the sample to be tested; The determination unit is used to perform the following steps: Auxiliary diagnosis is performed according to the system for auxiliary diagnosis of subcortical ischemic vascular dementia according to claim 2.
6. The device for assisting diagnosis of subcortical ischemic vascular dementia according to claim 5, characterized in that: The sample to be tested includes plasma.
7. The device for assisting diagnosis of subcortical ischemic vascular dementia according to claim 5 or 6, characterized in that: The detection method includes electrochemiluminescence detection method.
8. The device for assisting diagnosis of subcortical ischemic vascular dementia according to any one of claims 5 to 7, characterized in that: The device comprises a detection unit and a determination unit; The detection unit is used to perform the following steps: The concentration of placental growth factor in plasma was measured by electrochemiluminescence detection; The determination unit is used to perform the following steps: The concentration of placental growth factor in plasma is input into the system for auxiliary diagnosis of subcortical ischemic vascular dementia as described in claim 2 for auxiliary diagnosis.
9. A computer-readable storage medium having a computer program or instruction stored thereon, characterized in that: When the computer program or instruction is executed by a processor, the function of the device for assisting in diagnosing subcortical ischemic vascular dementia as claimed in any one of claims 5 to 8 is realized.
10. A computer device comprising a memory and a processor, wherein the memory stores a computer program or instruction, wherein: When the computer program or instruction is executed by a processor, the function of the device for assisting in diagnosing subcortical ischemic vascular dementia as claimed in any one of claims 5 to 8 is realized.
